128 related articles for article (PubMed ID: 2340349)
1. Oxcarbazepine disposition: preliminary observations in patients.
Kumps A; Wurth C
Biopharm Drug Dispos; 1990; 11(4):365-70. PubMed ID: 2340349
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactivity assessment of oxcarbazepine and its metabolites in the EMIT assay of carbamazepine plasma levels.
Kumps A; Mardens Y
Ther Drug Monit; 1986; 8(1):95-7. PubMed ID: 3515642
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug interactions in children taking oxcarbazepine.
Sallas WM; Milosavljev S; D'souza J; Hossain M
Clin Pharmacol Ther; 2003 Aug; 74(2):138-49. PubMed ID: 12891224
[TBL] [Abstract][Full Text] [Related]
5. Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.
Eadie MJ
Clin Pharmacokinet; 1991 Jul; 21(1):27-41. PubMed ID: 1914340
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.
Battino D; Estienne M; Avanzini G
Clin Pharmacokinet; 1995 Nov; 29(5):341-69. PubMed ID: 8582119
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta.
Pienimäki P; Lampela E; Hakkola J; Arvela P; Raunio H; Vähäkangas K
Epilepsia; 1997 Mar; 38(3):309-16. PubMed ID: 9070593
[TBL] [Abstract][Full Text] [Related]
8. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites.
Rouan MC; Lecaillon JB; Godbillon J; Menard F; Darragon T; Meyer P; Kourilsky O; Hillion D; Aldigier JC; Jungers P
Eur J Clin Pharmacol; 1994; 47(2):161-7. PubMed ID: 7859804
[TBL] [Abstract][Full Text] [Related]
9. First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.
Dickinson RG; Hooper WD; Dunstan PR; Eadie MJ
Eur J Clin Pharmacol; 1989; 37(1):69-74. PubMed ID: 2591466
[TBL] [Abstract][Full Text] [Related]
10. Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant.
Hooper WD; Dickinson RG; Dunstan PR; Pendlebury SC; Eadie MJ
Clin Exp Neurol; 1987; 24():105-12. PubMed ID: 3268334
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.
McKee PJ; Blacklaw J; Forrest G; Gillham RA; Walker SM; Connelly D; Brodie MJ
Br J Clin Pharmacol; 1994 Jan; 37(1):27-32. PubMed ID: 8148215
[TBL] [Abstract][Full Text] [Related]
12. Removal of 10-hydroxycarbazepine by plasmapheresis.
Christensen J; Balslev T; Villadsen J; Heinsvig EM; Dam M; Poulsen JH
Ther Drug Monit; 2001 Aug; 23(4):374-9. PubMed ID: 11477319
[TBL] [Abstract][Full Text] [Related]
13. First HPLC-UV method for rapid and simultaneous quantification of phenobarbital, primidone, phenytoin, carbamazepine, carbamazepine-10,11-epoxide, 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine, lamotrigine, oxcarbazepine and licarbazepine in human plasma.
Serralheiro A; Alves G; Fortuna A; Rocha M; Falcão A
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():1-9. PubMed ID: 23507454
[TBL] [Abstract][Full Text] [Related]
14. Transplacental passage of oxcarbazepine and its metabolites in vivo.
Myllynen P; Pienimäki P; Jouppila P; Vähäkangas K
Epilepsia; 2001 Nov; 42(11):1482-5. PubMed ID: 11879354
[TBL] [Abstract][Full Text] [Related]
15. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
Pisani F; Fazio A; Oteri G; Artesi C; Xiao B; Perucca E; Di Perri R
Acta Neurol Scand; 1994 Aug; 90(2):130-2. PubMed ID: 7801739
[TBL] [Abstract][Full Text] [Related]
16. Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine.
Hulsman JA; Rentmeester TW; Banfield CR; Reidenberg P; Colucci RD; Meehan JW; Radwanski E; Mojaverian P; Lin CC; Nezamis J
Clin Pharmacol Ther; 1995 Oct; 58(4):383-9. PubMed ID: 7586929
[TBL] [Abstract][Full Text] [Related]
17. Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock.
Borowicz KK; Malek R; Luszczki JJ; Ratnaraj N; Patsalos PN; Czuczwar SJ
Epilepsy Behav; 2007 Aug; 11(1):6-12. PubMed ID: 17602881
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on oxcarbazepine in epilepsy.
Bang LM; Goa KL
CNS Drugs; 2004; 18(1):57-61. PubMed ID: 14731060
[TBL] [Abstract][Full Text] [Related]
19. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19.
Lakehal F; Wurden CJ; Kalhorn TF; Levy RH
Epilepsy Res; 2002 Dec; 52(2):79-83. PubMed ID: 12458024
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid.
Tartara A; Galimberti CA; Manni R; Morini R; Limido G; Gatti G; Bartoli A; Strada G; Perucca E
Br J Clin Pharmacol; 1993 Oct; 36(4):366-8. PubMed ID: 12959317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
